Logo

Nucleonics Wins $1.6M from NIAID for RNAi-Based Hep B Study

Sep 26, 2003

NEW YORK, Sept. 26 (GenomeWeb News) - Malvern, Pa.-based Nucleonics announced yesterday that it had received a four-year, $1.6 million grant from the National Institute of Allergy and Infectious Disease to develop RNAi reagents and methods against the Hepatitis B virus.

 

The company will collaborate with the Scripps Research Institute and the Doylestown, Pa.-based Hepatitis B Foundation on the project, which will be aimed toward the eventual development of a therapeutic for Hepatits B.

 

Nucleonics uses expressed interfering RNA, or eiRNA, for its gene silencing techniques.

 

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.